Tags

45 pages

KOSDAQ

NextBiomedical: Nexpowder Downside, Nexphere-F Upside

Pharma Research Products: The PDRN Pioneer Behind Rejuran

KOSPI Closes Weak as Samsung Drags Breadth

APR Beauty Stock: Medicube, AGE-R and Korea's New Beauty Leader

Pearl Abyss: Crimson Desert Hits 4M and ₩223B Profit